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Chlamydia trachomatis infection, the most common reportable disease in the United States, can lead to pelvic
inflammatory disease (PID), infertility, ectopic pregnancy, and chronic pelvic pain. Although C. trachomatis
is identified among many women who receive a diagnosis of PID, the incidence and timing of PID and long-
term sequelae from an untreated chlamydial infection have not been fully determined. This article examines
evidence reviewed as part of the Centers for Disease Control and Prevention Chlamydia Immunology and
Control Expert Advisory Meeting; 24 reports were included. We found no prospective studies directly assessing
risk of long-term reproductive sequelae, such as infertility, after untreated C. trachomatis infection. Several
studies assessed PID diagnosis after untreated chlamydial infection, but rates varied widely, making it difficult
to determine an overall estimate. In high-risk settings, 2%–5% of untreated women developed PID within the
∼2-week period between testing positive for C. trachomatis and returning for treatment. However, the rate of
PID progression in the general, asymptomatic population followed up for longer periods appeared to be low.
According to the largest studies, after symptomatic PID of any cause has occurred, up to 18% of women may
develop infertility. In several studies, repeated chlamydial infection was associated with PID and other re-
productive sequelae, although it was difficult to determine whether the risk per infection increased with each
recurrent episode. The present review critically evaluates this body of literature and suggests future research
directions. Specifically, prospective studies assessing rates of symptomatic PID, subclinical tubal damage, and
long-term reproductive sequelae after C. trachomatis infection; better tools to measure PID and tubal damage;
and studies on the natural history of repeated chlamydial infections are needed.
Genital infection with Chlamydia trachomatis, the most
common reportable disease in the United States [1],
can lead to serious sequelae among women, including
pelvic inflammatory disease (PID), tubal factor infer-
tility, ectopic pregnancy, and chronic pelvic pain [2–7].
Approximately 8% of US women and 15% of Swedish
women have reported a PID diagnosis in their lifetimes
[8–10]. PID is thought to occur as microorganisms
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ascend from the lower genital tract, infecting and caus-
ing inflammation of the uterus, fallopian tubes, and
ovaries [11]. Although the microbial etiology of PID is
not fully delineated, C. trachomatis, Neisseria gonor-
rhoeae, Mycoplasma genitalium, and microorganisms
associated with bacterial vaginosis are frequently iso-
lated from the lower and upper genital tracts of women
with PID [12–17]. Although C. trachomatis is among
the most frequent pathogens associated with symptom-
atic PID [15, 18, 19], isolated in the upper genital tract
of up to a quarter of these patients [12, 18, 20], it has
also been associated with a wide spectrum of upper
genital tract pathology ranging from asymptomatic en-
dometritis [21–25] to symptomatic, laparoscopically
confirmed salpingitis [18]. This highlights the impor-
tance of this pathogen in the etiology of both acute
PID and subclinical upper tract disease. The reproduc-
tive and gynecologic consequences of PID, including
infertility [2, 7, 26, 27], ectopic pregnancy [2, 7, 26,
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28], recurrent PID [26, 28], and chronic pelvic pain [26–29],
can result from damage to the cilia lining the fallopian tubes,
fallopian tube blockage or closure, or adhesion formation
among pelvic organs.
Because of the potential for C. trachomatis infection to cause
serious sequelae, chlamydia screening and treatment programs
have been implemented in many countries to shorten the du-
ration of infection, prevent tubal damage among those infected,
and reduce C. trachomatis transmission. However, recent sur-
veillance data in several countries, including the United States,
suggest that chlamydia rates have not been decreasing, despite
ongoing control efforts [30, 31]. This has raised several fun-
damental questions about the natural history of C. trachomatis
infection [32]. For example, if C. trachomatis infections were
not detected and treated through a control program, what pro-
portion would result in sequelae? This influences the overall
potential benefit of the program and its cost-effectiveness. An
even more important consideration may be the timing of tubal
inflammation and damage relative to acquisition of infection.
This timing affects the likelihood that infections can be detected
and treated by a control program before development of symp-
tomatic PID or development of tubal damage that could ul-
timately lead to infertility or ectopic pregnancy. Contributing
to observed increases in chlamydia case rates is likely an increase
in repeat infections, which are common in some populations
[33]. Thus, another fundamental question is how harmful re-
peated C. trachomatis infections are in leading to sequelae. This
review was developed to address these key questions, which
were raised at the April 2008 Chlamydia Immunology and Con-
trol Expert Advisory Meeting sponsored by the Centers for
Disease Control and Prevention (CDC). This article critically
examines evidence addressing the risk and timing of female
reproductive tract sequelae after untreated C. trachomatis in-
fection and after repeated chlamydial infection. Gaps in knowl-
edge are identified, and future research needs are proposed.
METHODS
A 3-member committee was composed to systematically iden-
tify the literature for review. A search of the literature from
1950 through 2008 was conducted with the Medline comput-
erized database of the US National Library of Medicine. The
term “Chlamydia trachomatis” was combined with “pelvic in-
flammatory disease,” “salpingitis,” “endometritis,” “infertility,”
or “ectopic pregnancy.” A separate search was conducted as
follows: “pelvic inflammatory disease,” “salpingitis,” or “en-
dometritis” and “infertility” or “ectopic pregnancy.” This
yielded a total of 3308 citations. Citations were then limited to
human studies involving nonpregnant women, and postabor-
tion and transcervical instrumentation studies were excluded.
Additional articles were identified by cross-listing bibliogra-
phies of reviewed articles. The selected literature was examined
for content, and 24 articles deemed to be most relevant to the
key questions were selected for critical review. Six articles ex-
amined the prospective risk of PID after untreated chlamydial
infection [34–39], and 12 examined risk of long-term repro-
ductive sequelae after PID, including either PID of any cause
[7, 15, 27–29, 40] or C. trachomatis–associated PID [2, 4, 20,
26, 41, 42]. Two articles prospectively explored the risk of PID
after detected and treated chlamydial infection [43, 44], and 6
provided information on the risk of sequelae associated with
repeated infection [4, 7, 19, 45–47]. These studies are discussed
narratively in the text, and information on study design, pop-
ulation, methods, exposure and outcome measurement, results,
strengths, and limitations were tabulated (Tables 1–5).
RESULTS
What is the Risk of Sequelae over Time after an Untreated
C. trachomatis Infection?
The ultimate objective of chlamydia control programs is to
prevent the most serious long-term reproductive consequences
of C. trachomatis infection—mainly, infertility [48]. However,
this outcome may not be recognized for several years after a
chlamydial infection has caused tubal damage, because the af-
fected woman may not have tried to become pregnant. In ad-
dition, there are ethical and technical limitations in following
the natural course of infection, because an infection should be
treated promptly once it is detected. Thus, although a number
of case-control studies have demonstrated associations between
serologic evidence of past chlamydial infection and either tubal
factor infertility [5, 49–52] or ectopic pregnancy [3, 53, 54],
there are no prospective studies directly evaluating risk of long-
term reproductive tract morbidity after untreated C. trachom-
atis infection. PID can serve as a surrogate or intermediary
outcome, because its temporal relationship to both chlamydial
infection and long-term outcomes is more conducive to study
and because it has substantial morbidity and costs [8, 11].
Several studies have attempted to assess the proportion of un-
treated C. trachomatis infections leading to PID [34–39], and
another set of studies evaluated the proportion of PID cases
leading to infertility and ectopic pregnancy [2, 4, 7, 15, 20, 26–
29, 40–42]. Synthesizing these data can offer some insight into
the risk of long-term sequelae after untreated chlamydial
infection.
PID after untreated chlamydial infection. It is challenging
to assess the true incidence of PID among women with un-
treated C. trachomatis infection. Despite this, several studies
have described aspects of the natural history of untreated chla-
mydial infection (Table 1). In 3 investigations involving pop-
ulations at high risk, occurrence of clinically diagnosed PID in
women with untreated chlamydial infection was assessed during
the ∼14-day interval between testing and treatment. PID oc-
currence in this interval ranged from 2% to 4.5% among
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women returning for a follow-up visit [34–36]. In a study in
2 Baltimore sexually transmitted diseases (STD) clinics, 3 (3%)
of 93 women who tested positive for C. trachomatis by culture
developed PID within a median of 2 weeks between testing and
treatment [36]. Similarly, in a prospective STD clinic study
involving 129 adults who tested positive for C. trachomatis by
culture and nucleic acid amplification tests (NAATs), 2 women
(2%) received a diagnosis of PID at a treatment visit that oc-
curred a median of 13 days later [35]. Both of these women
had ongoing chlamydial infection, and one had acquired a new
gonococcal infection [35]. In a retrospective chart review study,
Bachmann et al [34] also investigated the occurrence of PID
during the period between testing and treatment in 67 mostly
symptomatic women who tested positive for C. trachomatis in
an emergency department or other high-risk clinical setting
and reported that 3 (4.5%) of 67 women who did not receive
therapy at the time of initial evaluation received a diagnosis of
PID when they returned for treatment.
If the mean rate observed in this 2-week period (∼3%) is
assumed to be constant and to apply to all women with chla-
mydia, it would be expected that close to 18% of women would
develop PID in 12 weeks, and 150% would develop PID in 1
year. However, 2 studies with longer follow-up periods did not
report such high rates of PID (Table 1). The first, conducted
in Sweden before the need to treat chlamydia was universally
accepted, comprised 109 asymptomatic adolescent girls with
untreated, culture-proven C. trachomatis infection, and 4
(3.7%) reported being hospitalized for salpingitis or seen in the
emergency department for lower abdominal pain and vaginal
discharge in the 3-month observation period [38]. In a more
recent long-term follow-up study involving 30 healthy adult
women who screened positive for C. trachomatis by NAAT, no
women developed symptoms of chlamydial infection, none re-
ceived C. trachomatis–specific antibiotic treatments, and none
received a diagnosis of PID from her general practitioner or
gynecologist within 1 year [37].
The highest estimate of PID after untreated chlamydial in-
fection comes from a randomized trial in which 20 women
coinfected with C. trachomatis and N. gonorrhoeae received
adequate therapy for gonococcal but not chlamydial infection
and were followed up for up to 7 weeks [39]. Six women (30%)
received a diagnosis of PID from clinicians who were masked
to the patients’ chlamydial culture results.
Infertility and ectopic pregnancy after PID. Several studies
have shown increased risks of reproductive and gynecologic
sequelae after PID of any cause (Table 2) [7, 15, 27–29, 40].
Most notably, a landmark prospective study of 2501 Swedish
women that was conducted by Westro¨m et al [7] from the
1960s through the 1980s found that 16% of women with la-
paroscopically confirmed salpingitis developed infertility, com-
pared with 2.7% of control women with clinically suspected
PID who did not have salpingitis determined by laparoscopic
examination. Infertility was defined by inability to conceive
after 1 year of attempting to become pregnant. Tubal factor
infertility was confirmed in 11.1% of cases and in none of the
control women. In addition, among women with salpingitis,
9.1% of first pregnancies were ectopic pregnancies, compared
with 1.4% of first pregnancies among control women. The
severity of PID on laparoscopic examination affected long-term
outcomes. Overall, 26% of women with clinically suspected PID
had normal-appearing tubes on laparascopy; none of these
women developed proven tubal factor infertility. Among
women with a mild episode of salpingitis, only 0.6% developed
tubal factor infertility, but 21% of those with a single episode
of severe salpingitis had tubal factor infertility in ensuing years
[7].
As part of a randomized controlled trial of treatment regi-
mens for PID (the PID Evaluation and Clinical Health
[PEACH] study), Ness et al [15] observed 831 women with
mild to moderate clinically suspected PID for adverse outcomes
during 1996–1999. Over a mean of 35 months of follow-up,
18% of the women reported infertility, 0.6% had an ectopic
pregnancy, and 29% had some degree of chronic pelvic pain,
with no differences by treatment arm. Among the 42% who
became pregnant, the mean time to pregnancy was 21 months
[15]. Laparoscopic verification of PID diagnoses, as done in
the study by Westro¨m et al [7], was not feasible in the PEACH
study; however, endometrial biopsy was performed for a subset
of 614 women [20, 41]. Rates of pregnancy, infertility, and
chronic pelvic pain were not significantly different between
women with and those without evidence of histologic endom-
etritis [20, 41].
Some studies have also assessed the risk of infertility after
PID that is specifically associated with C. trachomatis infection
(Table 3) [2, 4, 20, 26, 41, 42]. In a retrospective cohort study
involving 51 women hospitalized for PID in the 1980s, among
women suffering their first episode of PID, those who were
culture positive for C. trachomatis were more likely to expe-
rience involuntary infertility than were those who tested neg-
ative (relative risk, 2.5; 95% confidence interval [CI], 1.0–6.2)
[26]. Furthermore, in a study involving women hospitalized
during 1983–1987 for clinically suspected PID, 0 of 10 women
with gonococcal PID experienced an adverse reproductive out-
come, compared with 7 of 13 women with nongonococcal in-
fection [2]. However, in a more recent study involving 614
women with clinically suspected PID, women with endometrial
C. trachomatis infection had rates of subsequent infertility that
were similar to those among women who did not have C.
trachomatis detected in the endometrium (19% vs 16.8%) [20,
41]. In this study, endometritis and/or endometrial infection
with C. trachomatis or N. gonorrhoeae was not associated with
reduced pregnancy, elevated infertility, or increased chronic pel-
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vic pain [20, 41]. The reasons for this are unclear. Antichla-
mydial and gonococcal PID treatment might have reduced the
degree of damage preferentially in women with these infections
(compared with other causes of clinically suspected PID), and
endometritis does not always correlate with salpingitis [55–57].
In addition, women in all groups of this high-risk cohort may
have had prior or subsequent C. trachomatis infection that
resulted in tubal damage before or after the baseline PID ep-
isode, biasing results to the null. Indeed, a separate serologic
investigation in this cohort revealed an association between C.
trachomatis elementary body antibodies measured during the
final year of follow-up and lower pregnancy rates [4].
The symptoms of PID may be less severe with C. trachomatis
infection than with N. gonorrhoeae infection [58], which, in
turn, may cause women to delay care for PID. In a nested case-
control study in the cohort observed by Westro¨m et al [7],
among 76 case women who experienced infertility or ectopic
pregnancy and 337 control women with a subsequent intra-
uterine pregnancy after PID, C. trachomatis was not associated
with impaired fertility overall, compared with other causes of
PID (odds ratio [OR], 0.9; 95% CI, 0.5–1.7) [42]. Although C.
trachomatis infection was associated with delayed care (OR, 2.1;
95% CI, 1.0–4.1), which, in turn, was strongly associated with
impaired fertility (adjusted OR, 2.8; 95% CI, 1.3–6.1), prompt
treatment of chlamydia-associated PID dramatically lowered
risk of sequelae much more so than did prompt treatment of
gonococcal infection [42].
Summary. We found no prospective studies directly as-
sessing risk of infertility after untreated C. trachomatis infection,
and precise rates of progression are unknown. However, some
data are available on risk of PID after untreated chlamydial
infections and risk of infertility and other long-term outcomes
after PID. The rate of PID after untreated C. trachomatis genital
infection is challenging to determine accurately, because esti-
mates vary widely across studies. In STD clinic or other high-
risk populations in which untreated, detected chlamydial in-
fection was followed up for ∼2 weeks, rates of short-term PID
diagnosis ranged from 2% to 4.5% [34–36]. If these rates were
extrapolated to longer periods, we would expect a greater pro-
portion of patients to develop PID. However, in a population
of asymptomatic, untreated C. trachomatis–positive adolescent
girls seeking birth control in Sweden, PID occurred in 3.7%
over 12 weeks [38]. In the lowest-risk population evaluated
thus far, Morre´ et al [37] observed no PID developing in 30
healthy adult women followed up for 1 year. All of these studies
were relatively small and had limitations that could affect the
accuracy of risk estimates. Nonetheless, differences in these
results may be explained by several possible factors. First, PID
rates may not be constant over time for several reasons. A
disproportionate amount of PID might occur early in the
course of chlamydial infection, when care-seeking in STD clin-
ics or emergency departments is more likely because of recent
high-risk behavior or symptoms. Host factors may contribute,
with susceptible individuals developing tubal pathology early.
Higher organism load may also play a role. In addition, immune
responses developing over time could limit progression to the
upper genital tract even when the infection is not resolved at
the level of the cervix. Second, symptomatic infection prompt-
ing care-seeking may result in higher rates of PID than asymp-
tomatic infection (eg, because of differences in host response).
Third, there may be a lower threshold for PID diagnosis in
high-risk settings or with a known untreated infection. Finally,
PID rates may be higher in populations considered to be at
high risk of sexually transmitted infections, because they may
be more likely to have coinfections or bacterial vaginosis, have
a history of PID, or experience recurrent infection [44]. An-
other factor that may influence differences among rates is the
use of highly sensitive NAATs in some studies that may detect
infections with a lower C. trachomatis burden and, perhaps, a
lower likelihood for progression. The highest rates of PID were
seen in the small ( ) but widely cited study by Stammnp 20
et al [39]. Coinfection with N. gonorrhoeae and a greater like-
lihood for recurrent chlamydial infection in this particularly
high-risk population may explain the higher observed rate of
sequelae.
After symptomatic PID has occurred, even with treatment,
it is associated with significant reproductive and gynecologic
morbidity, including infertility, ectopic pregnancy, and chronic
pelvic pain [7, 15, 27–29, 40]. In the largest study of its kind,
from the 1960s through the 1980s in Sweden, Westro¨m et al
[7] found that 16% of women with laparoscopically verified
salpingitis developed infertility in the ensuing years, compared
with 2.7% of control women with clinically suspected PID but
no laparoscopic evidence of salpingitis. Ness et al [15] found
that 18% of women developed infertility after clinically diag-
nosed PID during the 1990s in the United States, and the rate
did not differ by presence or absence of histologic endometritis
in a subsequent analysis by Haggerty et al [20]. In the study
by Westro¨m et al [7], severity of PID, as judged by laparoscopic
examination, was associated with infertility, suggesting that tu-
bal damage sustained at the time of acute PID may lead to
sequelae [7, 29]. Among women with clinically suspected PID,
none of those with normal-appearing tubes developed tubal
factor infertility, whereas 21.4% of women with an episode of
severe salpingitis did [7]. Although PID of any cause is strongly
linked to sequelae [2, 4, 20, 26, 41, 42], data from the largest
studies suggest that chlamydial PID is no more or less likely
to lead to sequelae than other causes of PID [20, 41, 42].
When using PID as an intermediary outcome to estimate
risk of long-term reproductive sequelae resulting from un-
treated C. trachomatis infection, it is important to understand
the extent to which chlamydial infection may lead to these
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sequelae outside the pathway involving symptomatic PID. Most
women with tubal factor infertility and ectopic pregnancy have
no history of diagnosed PID, including women in case-control
studies showing strong associations between these outcomes
and serologic evidence of past chlamydial infection [3, 5, 49].
However, in one study, further questioning of infertile women
with no history of diagnosed PID revealed that 60% of those
with tubal infertility reported health care visits for abdominal
pain, compared with only 19% of those without tubal disease
[59]. Nonetheless, it is known that chlamydial infection can
cause asymptomatic or mildly symptomatic upper tract infec-
tion and inflammation [23, 25]. In addition, pathologic damage
in fallopian tube biopsy specimens from women with tubal
infertility is similar whether or not there is a history of overt
PID [60]. Subclinical tubal infection and inflammation likely
lead to some degree of infertility and other complications, but
the full extent to which this occurs remains unclear.
Research needs and future directions. Quantifying the
risks of PID, infertility, and ectopic pregnancy after untreated
C. trachomatis infection would provide vital data for chlamydia
control programs and for clinicians to share with patients on
the importance of screening to prevent sequelae. To better un-
derstand the risk and timing of sequelae after untreated C.
trachomatis infection, improvements must first be made in
measuring the short-term complications of chlamydial infec-
tion. All of the studies reviewed in Table 1 followed up women
for the development of clinically suspected PID and were there-
fore limited by the imprecise measurement of this outcome.
The studies were also unable to capture cases of asymptomatic
tubal inflammation and damage. As diagnostic misclassification
compromises not only the estimation of PID after an untreated
chlamydial infection but also sequelae after PID, it is of critical
importance to develop standardized and innovative methods
to ascertain both acute PID and subclinical tubal involvement
associated with chlamydial infection. To increase sensitivity, the
CDC recommends the minimum criteria for the diagnosis of
clinically suspected PID as either uterine or adnexal tenderness
or cervical motion tenderness [61]. However, this clinical ap-
proach, used by many studies to identify cases of PID, suffers
from extremely poor specificity [17]. Laparoscopic examination
or endometrial biopsies have been used by some studies to
confirm PID, with laparoscopic examination considered to be
the gold standard. However, neither of these confirmatory
methods is very precise. Compared with laparoscopically di-
agnosed salpingitis, histologically confirmed endometritis has
a sensitivity of 70%–89% and a specificity of 67%–92% [55–
57]. Even laparoscopic examination has been found to have an
extremely low sensitivity for the diagnosis of PID (25%–50%),
when compared with fimbrial minibiopsy showing histopath-
ologic evidence of PID [62, 63]. Furthermore, laparoscopic
examination, which lacks standardization and relies on subjec-
tive interpretation of pelvic structure photographs, has only a
fair intraobserver reproducibility for the diagnosis of PID
( ) and a poor to fair interobserver reproducibilitykp 0.58
( ) [62].kp 0.43
In addition to concerns about its sensitivity and standardi-
zation, laparoscopic examination is an invasive procedure and
is not routinely used in clinical practice. Noninvasive measures
of PID are needed not only to be more clinically feasible but
also to capture cases of subclinical tubal involvement in clinical
studies. Magnetic resonance imaging (MRI) has been investi-
gated as an alternative diagnostic procedure, although MRI
facilities are not widely available at settings where patients with
PID are typically seen. Data are limited, but those from at least
1 study ( ) suggest that MRI is sensitive (95%) and spe-np 30
cific (89%) for the diagnosis of PID, compared with laparos-
copic examination [64]. Transvaginal ultrasound is another
minimally invasive procedure, but it has a much lower sensi-
tivity for laparoscopically diagnosed PID (32%–81%) [64, 65].
Power Doppler, a recent innovation that allows improved de-
tection of blood flow and inflammation-induced hyperemia,
has been found in a study to have both high sensitivity (100%)
and high specificity (80%), compared with laparoscopic ex-
amination [66]. Lastly, vaginal white blood cell count was found
to be a sensitive marker of upper genital tract infection in a
study involving 121 women meeting the CDC’s minimal criteria
for PID [67]. More work is needed to verify the diagnostic
accuracy of these newer measures and additional inflammatory
markers, such as interferon and other cytokines.
Next, to fully understand the natural history and sequelae
of untreated chlamydial infection, we need additional pro-
spective studies assessing rates of both clinically suspected PID
and asymptomatic tubal inflammation after C. trachomatis in-
fection in diverse populations encompassing the full spectrum
of symptomatology and risk of sexually transmitted infection.
Additional information on the 12-month incidence of PID after
untreated C. trachomatis infection among asymptomatic col-
lege-aged women was recently collected as part of a randomized
trial of chlamydia screening in the United Kingdom that was
conducted before such screening was nationally recommended
there [68, 69]. Although final results of the study were published
too late for inclusion in this review, the natural history analysis
revealed that 9.5% of 74 women with untreated chlamydial
infection developed PID in 12 months [70]. Studying the timing
of PID occurrence is also critical. The picture emerging from
the studies listed in Table 1 suggests higher short-term rates of
PID, with risk of PID decreasing after the first few weeks, and
low rates within a year after asymptomatic infection. Under-
standing the timing of PID development is critical in optimizing
the frequency and structure of chlamydial screening and other
control strategies. Natural history studies are limited by the fact
that it would be unethical to withhold treatment for diagnosed
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chlamydial infection, and it is unclear how long a woman has
already had infection at the time it is detected through testing.
Nonetheless, creative strategies to develop prospective studies
of chlamydia natural history are vital. Innovative use of stored
genital specimens from existing or ongoing prospective studies
of other infections (eg, human papillomavirus vaccine trials
and human immunodeficiency virus prevention trials) in which
specimens are collected beyond those used to diagnose and
treat chlamydial infection as part of standard medical practice
might also provide opportunities for better understanding of
chlamydia natural history. Any study of C. trachomatis natural
history would have to be carefully designed to ensure protection
of human subjects. Finally, because of the challenges facing
accurate diagnosis of PID and the occurrence of asymptomatic
chlamydial upper tract involvement, as well as the difficulties
in obtaining better natural history data, primary and secondary
prevention strategies for C. trachomatis infection and its se-
quelae should be a focus of future studies, as discussed by
Gottlieb et al in this supplement [71].
A primary necessity for research on sequelae after PID is
identification of better, more proximal markers of tubal damage
that are predictive of long-term sequelae. This would not only
allow the outcomes of chlamydial infection to be more accu-
rately classified but would also make prospective research on
chlamydia and long-term outcomes more feasible. The land-
mark study by Westro¨m et al [7] provided excellent data on
risk of sequelae among women who were hospitalized with PID,
compared with a control group of women with abdominal pain
who did not have laparoscopically verified PID. However, these
data were obtained in Sweden 20–40 years ago in a potentially
much different microbiological and clinical milieu (eg, higher
prevalence of N. gonorrhoeae and older PID treatment regi-
mens). The PEACH study provided modern-day estimates of
adverse outcomes after mild to moderate PID in the United
States and stratified participants according to endometrial bi-
opsy results but did not include a control group of women
without clinically suspected PID [15]. Additional studies eval-
uating reproductive and gynecologic morbidity among women
with PID, compared with an appropriate control group, in a
modern-day setting would be valuable. In addition, prospective
studies evaluating the risk of reproductive sequelae after sub-
clinical upper genital tract infection and inflammation are
needed. Preliminary data from a prospective study showed that
17% of 58 women with subclinical endometritis at a baseline
visit had evidence of fallopian tube damage demonstrated by
hysterosalpingogram 3 months later, whereas only 8% of 362
women without endometritis had such evidence [72]. Final
results from this study have not yet been published. Finally,
current evidence suggests that the vast majority of women in-
fected with C. trachomatis do not develop PID, and not all
women with chlamydial PID become infertile. Host factors and
immunologic predictors explaining differences in morbidity
risk should be explored in future studies, as discussed by Dar-
ville et al in this supplement [73]. Differences in morbidity
after C. trachomatis infection may also be explained by simul-
taneous infection with other pathogens, such as N. gonorrhoeae
[15] and M. genitalium [74], and the impact of such coinfection
should be explored in future studies of PID and its sequelae.
Is the Risk of Sequelae Increased during a Repeat Chlamydial
Infection?
PID after 1 detected and treated chlamydial infection. A
prospective assessment of PID after detected and treated C.
trachomatis infection comes from a study of 1170 women from
5 US sites; all of the women were at high risk of chlamydia
based on their demographic risk scores (Table 4) [44]. The
women were tested for C. trachomatis and N. gonorrhoeae at
baseline and were retested at follow-up visits every 6–12 months
for a median of 3 years. Of these women, 122 tested positive
for C. trachomatis at baseline and received antibiotic therapy.
Twenty-three C. trachomatis–positive women (18.8%) received
a diagnosis of PID (primarily mild to moderate) during follow-
up. This rate of PID was substantially higher than that among
women who did not have gonococcal or chlamydial cervicitis
at baseline (7.0%). The etiology of subsequent PID episodes
was unknown. The incidence of severe PID from any cause,
stratified by C. trachomatis test history, was also assessed in a
retrospective cohort study involving 43,715 Swedish women
followed up from 1985 through 1999 [43]. Low et al [43] found
that, by 15 years of follow-up, 6% of women had tested positive
for C. trachomatis (and were assumed to have been treated),
4% of those who were screened and tested negative, and 3%
of those never screened were subsequently treated for PID.
Although some outpatient data were captured, most of the
registry data were from inpatient records and, therefore, pri-
marily measured the overall rate of severe PID. Women who
tested positive for C. trachomatis were 50% more likely to be
subsequently treated for PID than were women who tested
negative (hazard ratio [HR], 1.5; 95% confidence interval [CI],
1.2–1.8), although this relationship was attenuated when ad-
justed for demographic and socioeconomic factors (HR, 1.3;
95% CI, 1.0–1.6) [43].
Repeat infections with C. trachomatis are common [33, 75,
76] and may contribute to the higher incidence of PID among
women at high risk [39, 44], compared with women in the
general population [37]. Similarly, the higher risk of repeat
chlamydial infection among women with1 detected infection
may help explain the higher rates of PID associated with longer
follow-up of these women [43, 44].
PID after repeat chlamydial infection. The association be-
tween repeat infection and PID sequelae was assessed by a
retrospective cohort study involving 11,000 women and girls
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aged 10–44 years who tested positive for C. trachomatis in
Wisconsin during 1985–1992 (Table 5) [46]. Women who tested
positive twice were 4 times as likely (OR, 4.0; 95% CI, 1.6–9.9)
and women who tested positive 3 times were 16 times as
likely (OR, 6.4; 95% CI, 2.2–18.4) to receive a diagnosis of PID
[46]. It is difficult to determine the true impact of repeat chla-
mydial infection on PID from this study, however, because
clinicians may be more likely to diagnose PID in women with
a history of repeated chlamydial infection. Similarly, a pro-
spective cohort study involving 302 urban female sex workers
in Nairobi, Kenya, reported a significant relationship between
repeated C. trachomatis isolation and the cumulative risk of
chlamydial PID over ∼18 months (adjusted OR, 1.8; 95% CI,
1.3–2.4) [47]. However, the risk of PID with each individual
chlamydial infection appeared to be similar among those with
one infection and repeated infections [47], although the power
to detect a difference may have been limited. Thus, this study
suggests that, although cumulative risk increases, the risk of
PID per chlamydial infection may not be any greater with each
recurrent episode. Although these studies were unable to dis-
tinguish between persistent and new repeat infection, they sug-
gest that the risk of PID increases in parallel with the number
of detected C. trachomatis infections.
Further demonstration of the relationship between recurrent
chlamydial infection and risk of PID was evident in a pro-
spective study involving 443 women with clinically suspected
mild to moderate PID who were followed up for a mean of 84
months with repeated chlamydial serologic testing [4]. Al-
though baseline antibodies to C. trachomatis elementary bodies
were not associated with reproductive morbidity, rates of PID
recurrence were higher among women whose anti-chlamydial
antibodies were in the highest tertile during the final year of
follow-up (adjusted HR, 2.5; 95% CI, 1.0–6.3). Later serologic
testing, reflecting both baseline and subsequent chlamydial in-
fections, was associated with PID recurrence, suggesting that
additional exposures to C. trachomatis may increase the risk of
subsequent PID [4]. Supporting this was the finding that con-
sistent condom use in the same population was associated with
a marked decrease in the incidence of recurrent PID [19].
Long-term reproductive sequelae after repeat chlamydial
infection. In the same way that repeated chlamydial infection
may increase the risk of PID, recurrent infection with C. tra-
chomatis may also increase the risks of infertility and ectopic
pregnancy. There is good evidence to suggest that recurrent
PID increases sequelae risk, as first evidenced in the landmark
Scandinavian cohort study involving 1844 women with lapa-
roscopically confirmed salpingitis that was conducted by Wes-
tro¨m et al [7]. In this study, each episode of salpingitis roughly
doubled the risk of tubal factor infertility (8% after 1 episode,
20% after 2 episodes, and 40% after 3 episodes) [7]. Similarly,
the studies by Ness et al [4, 19], in which higher titers of anti-
chlamydial antibodies at follow-up and less consistent condom
use were linked with recurrent PID, also showed that these
factors were associated with longer times to pregnancy. These
findings suggest that additional exposures to C. trachomatis
after an episode of PID can lead to an increased risk of long-
term complications.
In the retrospective cohort study assessing diagnosed chla-
mydia and sequelae risk that was conducted by Hillis et al [46],
women who were identified as C. trachomatis positive 2 times
in Wisconsin county databases from 1985 through 1992 were
twice as likely (OR, 2.1; 95% CI, 1.3–3.4) and those with 3
diagnosed infections were 14 times as likely (OR, 4.5; 95% CI,
1.8–5.3) to be hospitalized with an ectopic pregnancy. Another
registry study involving 20,762 Norwegian women using the
health care system from 1990 through 2003 reported a similar
dose-response relationship between detected C. trachomatis in-
fection and ectopic pregnancy [45]. Compared with women
who tested negative for C. trachomatis, women with a history
of a diagnosed chlamydial infection had almost a 2-fold in-
creased risk of ectopic pregnancy (adjusted HR, 1.8; 95% CI,
1.1–3.0) and those with 2 diagnosed chlamydial infections
had a 3-fold increased risk of ectopic pregnancy (adjusted HR,
3.0; 95% CI, 1.6–5.6) [45].
Summary. Long-term follow-up studies of the period after
treated chlamydial infection show that women with 1 de-
tected C. trachomatis infection have higher rates of PID in the
ensuing years than do women without a detected infection,
with PID rates near 20% over 3 years in a high-risk population
[44]. Although a detected chlamydial infection may simply be
a marker for high-risk sexual behavior and exposure to other
sexually transmitted infections, one possible explanation for
these findings is an increased risk of PID related to repeated
C. trachomatis infections, which are common [75, 76].
Several studies have shown that the cumulative risk of PID
[4, 46, 47] and long-term reproductive sequelae [4, 45, 46]
increases with repeated chlamydial infections. However, it re-
mains unclear from these epidemiologic studies whether the
risk of sequelae from a given chlamydial infection is higher
with each additional repeat infection. Furthermore, method-
ological problems make it difficult to sort out how much of
the association between recurrent chlamydia and PID is at-
tributable to biologically plausible mechanisms and how much
is attributable to diagnostic ascertainment bias. Certainly, phy-
sicians’ knowledge about prior positive chlamydial results may
influence their differential diagnosis of lower abdominal pain.
Because of the asymptomatic nature of chlamydial infection, it
is also difficult to determine how many chlamydial infections
a woman has actually had, if she did not seek medical care.
Furthermore, it is difficult to determine whether a first diag-
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nosed infection is truly primary and how many past infections
have occurred when there is evidence of past infection. In all
of these studies, infections were detected and therefore treated;
however, perhaps the most enhanced pathologic memory im-
mune response may occur after an initial infection that has
resolved on its own. Lastly, the inability to distinguish between
persistent and repeat infection limits interpretation.
Research needs and future directions. Studies on the nat-
ural history of repeated chlamydial infections are needed. Such
studies should determine how the risk of PID in a given period
after a repeat infection compares with the risk of PID in an
equivalent period after an initial infection. In addition, because
it is difficult to determine whether a woman’s first diagnosed
chlamydial infection is truly primary, natural history studies
that conduct frequent C. trachomatis screenings and PID eval-
uations among a group of young, seronegative women are de-
sirable. To conduct these natural history studies, a better un-
derstanding of chlamydia-associated antibodies would be
valuable, in terms of the proportion of infections that result
in seroconversion, the time course of seroconversion, duration
of seroreactivity, and titers with initial and repeat infection.
Furthermore, better markers of repeat infection and immu-
nologic and host factors that predict worse tubal damage with
repeat infection should also be explored [73]. Because of the
high rates of PID from any cause in the years after a detected
chlamydial infection in some populations [44], we also need
studies of prevention strategies focused on women who have
already received a diagnosis of at least one chlamydial infection.
Recently, Ness et al [19] reported that consistent condom use
was associated with a 30%–60% reduction in recurrent PID in
a subgroup of 684 sexually active women followed up after an
initial episode of PID. However, additional studies are needed
to confirm these data and to determine optimal prevention
strategies after diagnosed chlamydial infection in addition to
those after PID.
CONCLUSION
Although the evidence linking C. trachomatis with tubal pa-
thology is strong, there remains a great deal of uncertainty
about the progression rates of both PID and reproductive se-
quelae among women acquiring C. trachomatis infection. Fur-
thermore, the ability to link a specific chlamydial infection with
later reproductive and gynecologic morbidity is limited. Pro-
spective studies assessing the rates of symptomatic PID, asymp-
tomatic tubal damage, and reproductive sequelae after C. tra-
chomatis infection; better tools to measure PID and tubal
damage; and studies on the natural history of repeated chla-
mydial infections are needed to better understand the long-
term risks of chlamydial infection.
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